Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 16

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 8
Chunk 16
---
On
December 15, 2024, the Company entered into a Strategic Services Agreement (the “Dominant Treasure Agreement”) with Dominant
Treasure Health Company Limited (“Dominant Treasure”). Pursuant to the terms of the Dominant Treasure Agreement, Dominant
Treasure agreed to provide certain services to the Company to assist the Company in accelerating the Company’s desire to get its
products developed and distributed in the Southeast Asian market. In exchange for Dominant Treasure’s has services pursuant to
the Dominant Treasure Agreement, the Company agreed to pay Dominant Treasure a one-time payment of $2,300,000. In addition, if Dominant
Treasure is involved in generating negotiations and conclusion of a distribution agreement for the Company in the countries of China
(including Hong Kong), Singapore and Malaysia, the Company will pay Dominant Treasure a success fee of 5% of any upfront and/or milestone
payments to be received by the Company. If such an agreement includes a royalty payment to the Company, Dominant Treasure will receive
5% of such royalty payment. The Dominant Treasure Agreement has a term of 36 months and may be terminated at any time upon mutual agreement
of the parties. The one-time payment of $2,300,000 was accounted for as a prepaid contract and expensed over three-year period. For the
three and nine months ended September 30, 2025, the Company recorded consulting expense related to the Dominant Treasure agreement totaling
$193,242 and $573,425.

    21

JUPITER
NEUROSCIENCES, INC.

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note
7 – Commitments and Contingencies, continued

Licensing
and Royalty Agreements - Aquanova AG

In
September 2016, the Company entered into a Development, Collaboration and License Agreement (“License Agreement”) with Aquanova
AG, a German company in the field of development, manufacturing and selling of colloidal formulas. The License Agreement resulted in
the creation of the pharmaceutical product, JOTROL. The License Agreement remains in effect until product launch, which is undeterminable
at this time. The Chief Scientific Officer of the Company and the CEO of Aquanova are the joint inventors of JOTROL. Aquanova is the
assignee on the patents in the United States, the European Union, China and Japan whereas the Company is obligated to maintain the patents.
The License Agreement grants